Asthma usually presents with symptoms of wheeze, dyspnoea and cough. However, clinicians should be aware of atypical presentation of this disorder when cough is the main or only symptom in conditions such as cough-variant asthma, nonasthmatic eosinophilic bronchitis and atopic cough. Early diagnosis and treatment of these conditions with inhaled corticosteroids improves symptoms in the majority of patients. Up to 10% of patients with asthma remain poorly controlled in spite of optimal standard therapy. These patients have been encompassed under the term ‘treatment-refractory asthma’ (TRA), have the greatest morbidity and are responsible for more than 50% of healthcare costs. In this review we discuss investigations, management and pathophysiology of the various phenotypes of atypical presentations of asthma as well as novel biological agents licensed and those that have been reported in clinical trials in terms of their efficacy and safety in TRA.
AzzawiM.JohnstonP.W.MajumdarS.KayA.B.JefferyP.K. (1992) T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Respir Dis145: 1477–1482.
4.
BatemanE.D.BousheyH.A.BousquetJ.BusseW.W.ClarkT.J.PauwelsR.A. (2004) Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med170: 836–844.
5.
BeasleyR.AldingtonS. (2007) Magnesium in the treatment of asthma. Curr Opin Allergy Clin Immunol7: 107–110.
6.
BerryM.A.HargadonB.ShelleyM.ParkerD.ShawD.E.GreenR.H. (2006) Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med354: 697–708.
7.
BlackP.N.ScicchitanoR.JenkinsC.R.BlasiF.AllegraL.WlodarczykJ. (2000) Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. Eur Respir J15: 254–259.
8.
BouletL.P.ChapmanK.R.CoteJ.KalraS.BhagatR.SwystunV.A. (1997) Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med155: 1835–1840.
9.
BousquetJ.CabreraP.BerkmanN.BuhlR.HolgateS.WenzelS. (2005) The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy60: 302–308.
10.
BousquetJ.WenzelS.HolgateS.LumryW.FreemanP.FoxH. (2004) Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest125: 1378–1386.
11.
BramanS.S. (2006) The global burden of asthma. Chest130: 4S–12S.
12.
BramanS.S.CorraoW.M. (1985) Chronic cough. Diagnosis and treatment. Prim Care12: 217–225.
13.
Brightling, C.E. (2006) Chronic cough due to non-asthmatic eosinophilic bronchitis. ACCP evidence based clinical practice guidelines. Chest 129: 116s–121s.
14.
BrightlingC.E.BraddingP.SymonF.A.HolgateS.T.WardlawA.J.PavordI.D. (2002) Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med346: 1699–1705.
15.
BrightlingC.E.PavordI.D. (2000) Eosinophilic bronchitis - what is it and why is it important?Clin Exp Allergy30: 4–6.
16.
BrightlingC.E.SymonF.A.BirringS.S.BraddingP.WardlawA.J.PavordI.D. (2003) Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax58: 528–532.
17.
BrightlingC.E.WardR.GohK.L.WardlawA.J.PavordI.D. (1999a) Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med160: 406–410.
18.
BrightlingC.E.WardR.WardlawA.J.PavordI.D. (2000a) Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis. Eur Respir J15: 682–686.
19.
BrightlingC.E.WardR.WoltmannG.BraddingP.ShellerJ.R.DworskiR. (2000b) Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med162: 878–882.
20.
BrightlingC.E.WoltmannG.WardlawA.J.PavordI.D. (1999b) Development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma. Eur Respir J14: 1228–1230.
21.
BTS/SIGN (2008) BTS/Sign (British Thoracic Society/Scottish Intercollegiate Network). British Guideline on the Management of Asthma: A National Clinical Guideline. Thorax63(Suppl. IV): iv1–iv121.
22.
BusseW.CorrenJ.LanierB.Q.McalaryM.Fowler-TaylorA.CioppaG.D. (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol108: 184–190.
23.
BusseW.W.IsraelE.NelsonH.S.BakerJ.W.CharousB.L.YoungD.Y. (2008) Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med178: 1002–1008.
24.
ButtnerC.LunA.SplettstoesserT.KunkelG.RenzH. (2003) Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J21: 799–803.
25.
CarneyI.K.GibsonP.G.Murree-AllenK.SaltosN.OlsonL.G.HensleyM.J. (1997) A systematic evaluation of mechanisms in chronic cough. Am J Respir Crit Care Med156: 211–216.
26.
ChanezP.WenzelS.E.AndersonG.P.AntoJ.M.BelE.H.BouletL.P. (2007) Severe asthma in adults: what are the important questions?J Allergy Clin Immunol119: 1337–1348.
27.
ChippsB.CorrenJ.FinnA.HedgecockS.FoxH.BloggM. (2005) Omalizumab significantly improves quality of life in patients with severe persistent asthma. J Allergy Clin Immunol115: S5–S19.
28.
ChungK.F.HewM.ScoreJ.JonesA.V.ReiterA.CrossN.C. (2006) Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity. Eur Respir J27: 230–232.
29.
ChungK.F.PavordI.D. (2008) Prevalence, pathogenesis, and causes of chronic cough. Lancet371: 1364–1374.
30.
CookP.J.DaviesP.TunnicliffeW.AyresJ.G.HoneybourneD.WiseR. (1998) Chlamydia pneumoniae and asthma. Thorax53: 254–259.
31.
CorraoW.M.BramanS.S.IrwinR.S. (1979) Chronic cough as the sole presenting manifestation of bronchial asthma. N Engl J Med300: 633–637.
32.
CorrenJ.BusseW.MeltzerE.O.MansfieldL.BenschG.FahrenholzJ. (2010) A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med181: 788–796.
33.
CorryD.B.KheradmandF. (1999) Induction and regulation of the IgE response. Nature402: B18–B23.
34.
CruzA.A.LimaF.SarinhoE.AyreG.MartinC.FoxH. (2007) Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy37: 197–207.
35.
CunninghamA.F.JohnstonS.L.JuliousS.A.LampeF.C.WardM.E. (1998) Chronic Chlamydia pneumoniae infection and asthma exacerbations in children. Eur Respir J11: 345–349.
36.
De DiegoA.MartinezE.PerpinaM.NietoL.CompteL.MacianV. (2005) Airway inflammation and cough sensitivity in cough-variant asthma. Allergy60: 1407–1411.
37.
DesaiD.BrightlingC. (2009) Cytokine and anti-cytokine therapy in asthma: ready for the clinic?Clin Exp Immunol158: 10–19.
38.
DicpinigaitisP.V. (2006) Chronic cough due to asthma: ACCP evidence-based clinical practice guidelines. Chest129: 75S–79S.
39.
DicpinigaitisP.V.DobkinJ.B.ReichelJ. (2002) Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J Asthma39: 291–297.
40.
European Network for Understanding Mechanisms of Severe Asthma (2003) The Enfumosa cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J22: 470–477.
41.
FahyJ.V.FlemingH.E.WongH.H.LiuJ.T.SuJ.Q.ReimannJ. (1997) The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med155: 1828–1834.
42.
FinnA.GrossG.Van BavelJ.LeeT.WindomH.EverhardF. (2003) Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol111: 278–284.
43.
Flood-PageP.Menzies-GowA.PhippsS.YingS.WangooA.LudwigM.S. (2003a) Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest112: 1029–1036.
44.
Flood-PageP.SwensonC.FaifermanI.MatthewsJ.WilliamsM.BrannickL. (2007) A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med176: 1062–1071.
45.
Flood-PageP.T.Menzies-GowA.N.KayA.B.RobinsonD.S. (2003b) Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med167: 199–204.
46.
FujimuraM.AboM.OgawaH.NishiK.KibeY.HiroseT. (2005a) Importance of atopic cough, cough variant asthma and sinobronchial syndrome as causes of chronic cough in the Hokuriku area of Japan. Respirology10: 201–207.
47.
FujimuraM.HaraJ.MyouS. (2005b) Change in bronchial responsiveness and cough reflex sensitivity in patients with cough variant asthma: effect of inhaled corticosteroids. Cough1: 5–5.
48.
FujimuraM.NishizawaY.NishitsujiM.NomuraS.AboM.OgawaH. (2005c) Predictors for typical asthma onset from cough variant asthma. J Asthma42: 107–111.
49.
FujimuraM.OgawaH. (2003) Atopic cough: little evidence to support a new clinical entity. Thorax58: 737–737.
50.
FujimuraM.OgawaH.NishizawaY.NishiK. (2003) Comparison of atopic cough with cough variant asthma: is atopic cough a precursor of asthma?Thorax58: 14–18.
51.
FujimuraM.OgawaH.YasuiM.MatsudaT. (2000) Eosinophilic tracheobronchitis and airway cough hypersensitivity in chronic non-productive cough. Clin Exp Allergy30: 41–47.
52.
FujimuraM.OhkuraN.AboM.FurushoS.WasedaY.IchikawaY. (2008) Exhaled nitric oxide levels in patients with atopic cough and cough variant asthma. Respirology13: 359–364.
53.
FujimuraM.SakamotoS.MatsudaT. (1992) Bronchodilator-resistive cough in atopic patients: bronchial reversibility and hyperresponsiveness. Intern Med31: 447–452.
54.
FujimuraM.SongurN.KamioY.MatsudaT. (1997) Detection of eosinophils in hypertonic saline-induced sputum in patients with chronic nonproductive cough. J Asthma34: 119–126.
55.
GibsonP.G.DolovichJ.DenburgJ.RamsdaleE.H.HargreaveF.E. (1989) Chronic cough: eosinophilic bronchitis without asthma. Lancet1: 1346–1348.
56.
GibsonP.G.FujimuraM.NiimiA. (2002) Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax57: 178–182.
57.
GibsonP.G.ZlaticK.ScottJ.SewellW.WoolleyK.SaltosN. (1998) Chronic Cough resembles asthma with IL-5 and granulocyte-macrophage colony-stimulating factor gene expression in bronchoalveolar cells. J Allergy Clin Immunol101: 320–326.
58.
GouldH.J.SuttonB.J. (2008) IgE in allergy and asthma today. Nat Rev Immunol8: 205–217.
GrunigG.WarnockM.WakilA.E.VenkayyaR.BrombacherF.RennickD.M. (1998) Requirement for IL-13 independently of IL-4 in experimental asthma. Science282: 2261–2263.
61.
HaldarP.BrightlingC.E.HargadonB.GuptaS.MonteiroW.SousaA. (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med360: 973–984.
62.
HaldarP.PavordI.D.ShawD.E.BerryM.A.ThomasM.BrightlingC.E. (2008) Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med178: 218–224.
63.
HamiltonL.M.Torres-LozanoC.PuddicombeS.M.RichterA.KimberI.DearmanR.J. (2003) The role of the epidermal growth factor receptor in sustaining neutrophil inflammation in severe asthma. Clin Exp Allergy33: 233–240.
64.
HammerschlagM.R. (2000) Chlamydia pneumoniae and the lung. Eur Respir J16: 1001–1007.
65.
HoffsteinV. (1994) Persistent cough in nonsmokers. Can Respir J1: 40–47.
66.
HolgateS.T.ChuchalinA.G.HebertJ.LotvallJ.PerssonG.B.ChungK.F. (2004) Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy34: 632–638.
67.
HolgateS.T.PolosaR. (2006) The mechanisms, diagnosis, and management of severe asthma in adults. Lancet368: 780–793.
68.
HowarthP.H.BabuK.S.ArshadH.S.LauL.C.BuckleyM.G.McconnellW. (2005) Tumour necrosis factor (TNF{alpha}) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax60: 1012–1018. Epub 15 September 2005.
69.
HumbertM.BeasleyR.AyresJ.SlavinR.HebertJ.BousquetJ. (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): innovate. Allergy60: 309–316.
70.
HumbertM.De BlayF.GarciaG.Prud'hommeA.LeroyerC.MagnanA. (2009) Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy64: 1194–1201.
71.
IngramJ.L.BonnerJ.C. (2006) EGF and PDGF receptor tyrosine kinases as therapeutic targets for chronic lung diseases. Curr Mol Med6: 409–421.
72.
IrwinR.S.BaumannM.H.BolserD.C.BouletL.P.BramanS.S.BrightlingC.E. (2006) Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest129: 1S–23S.
73.
IrwinR.S.CorraoW.M.PratterM.R. (1981) Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy. Am Rev Respir Dis123: 413–417.
74.
IrwinR.S.CurleyF.J.FrenchC.L. (1990) Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis141: 640–647.
75.
IrwinR.S.FrenchC.T.SmyrniosN.A.CurleyF.J. (1997) Interpretation of positive results of a methacholine inhalation challenge and 1 week of inhaled bronchodilator use in diagnosing and treating cough-variant asthma. Arch Intern Med157: 1981–1987.
76.
JatakanonA.UasufC.MaziakW.LimS.ChungK.F.BarnesP.J. (1999) Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med160: 1532–1539.
77.
JohnsonD.OsbornL.M. (1991) Cough variant asthma: a review of the clinical literature. J Asthma28: 85–90.
78.
KanazawaH.EguchiY.NomuraN.YoshikawaJ. (2005) Analysis of vascular endothelial growth factor levels in induced sputum samples from patients with cough variant asthma. Ann Allergy Asthma Immunol95: 266–271.
KastelikJ.A.AzizI.OjooJ.C.ThompsonR.H.RedingtonA.E.MoriceA.H. (2005) Investigation and management of chronic cough using a probability-based algorithm. Eur Respir J25: 235–243.
81.
KitaT.FujimuraM.OgawaH.NakatsumiY.NomuraS.IshiuraY. (2010) Antitussive effects of the leukotriene receptor antagonist montelukast in patients with cough variant asthma and atopic cough. Allergol Int59: 185–192.
82.
KonO.M.KayA.B. (1999) Anti-T cell strategies in asthma. Inflamm Res48: 516–523.
83.
KrishnamoorthyN.OrissT.B.PagliaM.FeiM.YarlagaddaM.VanhaesebroeckB. (2008) Activation of c-kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med14: 565–573.
84.
LeckieM.J.Ten BrinkeA.KhanJ.DiamantZ.O'connorB.J.WallsC.M. (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet356: 2144–2148.
85.
LeffJ.A.BusseW.W.PearlmanD.BronskyE.A.KempJ.HendelesL. (1998) Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med339: 147–152.
86.
MartinR.J.KraftM.ChuH.W.BernsE.A.CassellG.H. (2001) A link between chronic asthma and chronic infection. J Allergy Clin Immunol107: 595–601.
87.
MatsumotoH.NiimiA.TabuenaR.P.TakemuraM.UedaT.YamaguchiM. (2007) Airway wall thickening in patients with cough variant asthma and nonasthmatic chronic cough. Chest131: 1042–1049.
88.
MatsumotoH.NiimiA.TakemuraM.UedaT.TabuenaR.YamaguchiM. (2006) Prognosis of cough variant asthma: a retrospective analysis. J Asthma43: 131–135.
89.
McgarveyL.MoriceA.H. (2003) Atopic cough: little evidence to support a new clinical entity. Thorax58: 736–737. author reply 737-738.
90.
McgarveyL.P.HeaneyL.G.LawsonJ.T.JohnstonB.T.ScallyC.M.EnnisM. (1998) Evaluation and outcome of patients with chronic non-productive cough using a comprehensive diagnostic protocol. Thorax53: 738–743.
91.
MelloC.J.IrwinR.S.CurleyF.J. (1996) Predictive values of the character, timing, and complications of chronic cough in diagnosing its cause. Arch Intern Med156: 997–1003.
92.
MenziesD.HolmesL.MccumeskyG.Prys-PicardC.NivenR. (2011) Aspergillus sensitization is associated with airflow limitation and bronchiectasis in severe asthma. Allergy66: 679–685.
93.
Menzies-GowA.Flood-PageP.SehmiR.BurmanJ.HamidQ.RobinsonD.S. (2003) Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol111: 714–719.
94.
Menzies-GowA.RobinsonD.S. (2002) Eosinophils, eosinophilic cytokines (interleukin-5), and antieosinophilic therapy in asthma. Curr Opin Pulm Med8: 33–38.
95.
MilgromH.BergerW.NayakA.GuptaN.PollardS.McalaryM. (2001) Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics108: E36–E36.
96.
MilgromH.FickR.B.Jr, SuJ.Q.ReimannJ.D.BushR.K.WatrousM.L. (1999) Treatment of allergic asthma with monoclonal anti-IgE antibody. Rhumab-E25 Study Group. N Engl J Med341: 1966–1973.
97.
MillarM.M.McgrathK.G.PattersonR. (1998) Malignant cough equivalent asthma: definition and case reports. Ann Allergy Asthma Immunol80: 345–351.
98.
MoriceA.H.FontanaG.A.BelvisiM.G.BirringS.S.ChungK.F.DicpinigaitisP.V. (2007) ERS guidelines on the assessment of cough. Eur Respir J29: 1256–1276.
99.
MoriceA.H.KastelikJ.A. (2003) Cough. 1: chronic cough in adults. Thorax58: 901–907.
100.
MoriceA.H.McgarveyL.PavordI. (2006) Recommendations for the management of cough in adults. Thorax61(Suppl. 1): i1–i24.
101.
MorjariaJ.B.BabuK.S.HolgateS.T.PolosaR. (2006) Tumour necrosis factor alpha as a therapeutic target in asthma. Drug Discovery Today: Therapeutic Strategies3: 309–316.
102.
MorjariaJ.B.ChauhanA.J.BabuK.S.PolosaR.DaviesD.E.HolgateS.T. (2008) The role of a soluble TNF-a receptor fusion protein (etanercept) in corticosteroid-refractory asthma: a double blind, randomised placebo-controlled trial. Thorax63: 584–591.
103.
MorjariaJ.B.GnanakumaranG.BabuK.S. (2007) Anti-IgE in allergic asthma and rhinitis: an update. Expert Opin Biol Ther7: 1739–1747.
104.
MorjariaJ.B.PolosaR. (2010) Recommendation for optimal management of severe refractory asthma. J Asthma Allergy3: 43–56.
105.
NairP.PizzichiniM.M.KjarsgaardM.InmanM.D.EfthimiadisA.PizzichiniE. (2009) Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med360: 985–993.
NiimiA.MatsumotoH.MinakuchiM.KitaichiM.AmitaniR. (2000) Airway remodelling in cough-variant asthma. Lancet356: 564–565.
109.
OgawaH.FujimuraM.TofukuY. (2004) Treatment of atopic cough caused by basidiomycetes antigen with low-dose itraconazol. Lung182: 279–284.
110.
PalombiniB.C.VillanovaC.A.AraujoE.GastalO.L.AltD.C.StolzD.P. (1999) A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease. Chest116: 279–284.
111.
ParkC.S.LeeS.M.ChungS.W.UhS.KimH.T.KimY.H. (1994) Interleukin-2 and soluble interleukin-2 receptor in bronchoalveolar lavage fluid from patients with bronchial asthma. Chest106: 400–406.
112.
PetersS.P.KunselmanS.J.IcitovicN.MooreW.C.PascualR.AmeredesB.T. (2011) Tiotropium bromide step-up therapy for adults with uncontrolled asthma. New Engl J Med363: 1715–1726.
113.
PoeR.H.HarderR.V.IsraelR.H.KallayM.C. (1989) Chronic persistent cough. Experience in diagnosis and outcome using an anatomic diagnostic protocol. Chest95: 723–728.
114.
PolosaR.BenfattoG.T. (2009) Managing patients with chronic severe asthma: rise to the challenge. Eur J Intern Med20: 114–124.
115.
PolosaR.MorjariaJ. (2008) Immunomodulatory and biologic therapies for severe refractory asthma. Respir Med102: 1499–1510.
116.
PrestaL.ShieldsR.O'connellL.LahrS.PorterJ.GormanC. (1994) The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem269: 26368–26373.
117.
ReberL.Da SilvaC.A.FrossardN. (2006) Stem cell factor and its receptor c-kit as targets for inflammatory diseases. Eur J Pharmacol533: 327–340.
118.
RobertsG.NewsomD.GomezK.RafflesA.SaglaniS.BegentJ. (2003) Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial. Thorax58: 306–310.
119.
RobinsonD.S.BentleyA.M.HartnellA.KayA.B.DurhamS.R. (1993) Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. Thorax48: 26–32.
120.
RollingC.TretonD.PellegriniS.GalanaudP.RichardY. (1996) IL4 and IL13 receptors share the gamma C chain and activate Stat6, Stat3 and Stat5 proteins in normal human B cells. FEBS Lett393: 53–56.
121.
RothenbergM.E.HoganS.P. (2006) The eosinophil. Annu Rev Immunol24: 147–174.
122.
SandersonC.J. (1992) Interleukin-5, eosinophils, and disease. Blood79: 3101–3109.
123.
SilvermanR.A.OsbornH.RungeJ.GallagherE.J.ChiangW.FeldmanJ. (2002) IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest122: 489–497.
124.
SimonD.BraathenL.R.SimonH.U. (2004) Eosinophils and atopic dermatitis. Allergy59: 561–570.
125.
SmyrniosN.A.IrwinR.S.CurleyF.J. (1995) Chronic cough with a history of excessive sputum production. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Chest108: 991–997.
126.
SolerM.MatzJ.TownleyR.BuhlR.O'brienJ.FoxH. (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J18: 254–261.
127.
StephensR.S. (2003) The cellular paradigm of chlamydial pathogenesis. Trends Microbiol11: 44–51.
128.
Ten BrinkeA.Van DisselJ.T.SterkP.J.ZwindermanA.H.RabeK.F.BelE.H. (2001) Persistent airflow limitation in adult-onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infection. J Allergy Clin Immunol107: 449–454.
129.
TonelliM.ZingoniM.BacciE.DenteF.L.Di FrancoA.GianniniD. (2003) Short-term effect of the addition of leukotriene receptor antagonists to the current therapy in severe asthmatics. Pulm Pharmacol Ther16: 237–240.
VatrellaA.PonticielloA.PelaiaG.ParrellaR.CazzolaM. (2005) Bronchodilating effects of salmeterol, theophylline and their combination in patients with moderate to severe asthma. Pulm Pharmacol Ther18: 89–92.
132.
VignolaA.M.HumbertM.BousquetJ.BouletL.P.HedgecockS.BloggM. (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy59: 709–717.
133.
Von HertzenL.C. (2002) Role of persistent infection in the control and severity of asthma: focus on Chlamydia pneumoniae. Eur Respir J19: 546–556.
134.
WarkP.A.JohnstonS.L.SimpsonJ.L.HensleyM.J.GibsonP.G. (2002) Chlamydia pneumoniae immunoglobulin a reactivation and airway inflammation in acute asthma. Eur Respir J20: 834–840.
135.
WebbD.C.MckenzieA.N.KoskinenA.M.YangM.MattesJ.FosterP.S. (2000) Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol165: 108–113.
136.
WenzelS.FahyJ.V.IrvinC.G.PetersS.P.SpectorS.SzeflerS.J. (2000) Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations and unanswered questions. Am J Respir Crit Care Med162: 2341–2351.
137.
WenzelS.E.BarnesP.J.BleeckerE.R.BousquetJ.BusseW.DahlenS.E. (2009) A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med179: 549–558.
138.
WenzelS.E.SchwartzL.B.LangmackE.L.HallidayJ.L.TrudeauJ.B.GibbsR.L. (1999) Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med160: 1001–1008.
139.
Wills-KarpM.LuyimbaziJ.XuX.SchofieldB.NebenT.Y.KarpC.L. (1998) Interleukin-13: central mediator of allergic asthma. Science282: 2258–2261.
